Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midazolam + dexmedetomidine
- Development stage
- Unknown
- Lead developer
- University of Alexandria
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This combination sedation regimen consists of nebulized midazolam and dexmedetomidine, specifically investigated for managing dental anxiety in preschool children. Midazolam is a short-acting benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, providing anxiolytic and sedative effects. Dexmedetomidine is a potent and highly selective alpha-2 adrenergic agonist that acts on receptors in the central nervous system to induce sedation and analgesia without significant respiratory depression. The combination is administered via nebulization to provide a non-invasive, moderate sedation for pediatric patients undergoing dental procedures.
- Other names
- nebulized midazolam and dexmedetomidine
02
Targets
ADRA2A (α2A)GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on midazolam + dexmedetomidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midazolam + dexmedetomidine.